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The RNA Activator ds-p21 Potentiates the Cytotoxicity
Induced by Fludarabine in Dohh2 Cells
Francesca Patella,1,2* Serena Lucotti,1* Milena Rizzo,1 Monica Evangelista,1 and Giuseppe Rainaldi1,3
Recently, it has been reported that, in several tumor cell lines, short double-stranded RNAs tailored for promoter
regions of specific genes are able to activate their transcription. Such molecules (named RNA activators) act
opposite to other double-stranded RNA molecules (named RNA inhibitors) in that the overexpression instead of
underexpression of a given gene is triggered. In Dohh2 non-Hodgkin lymphoma cells, the transcriptional re-
pressor BCL6, which negatively controls both p53 and p21, is overexpressed, so that the cells can escape the
check point governed by p53 and proliferate. The aim of this work was to investigate whether the RNA activator
p21 can represent a tool to circumvent the transcriptional control of BCL6 and induce the blockage of cell
proliferation in Dohh2 non-Hodgkin lymphoma cells. For that, Dohh2 cells were transfected with either a control
RNA activator (ds-NC) or an RNA activator specific for human p21 promoter (ds-p21). At various time points
after transfection, the cells were collected and p21 was measured. Dohh2 cells transfected with ds-p21 showed a
slight but significant overexpression of p21 at both mRNA and protein levels. Nonetheless, cell proliferation, cell
cycle, and apoptosis were not significantly modified. In contrast, the exposure of Dohh2 cells transfected with
ds-p21 to fludarabine potentiates the cytotoxicity of the drug, suggesting the RNA activator p21 complements
the fludarabine-dependent cell death pathways.
Introduction
Tumor cells have a high proliferation rate mostlybecause of cell cycle deregulation. Cell cycle is controlled
by a complex network of cyclins, and cyclin-dependent ki-
nases are the core of this network. P21 being an inhibitor of
cyclin-dependent kinases is a negative regulator of cell cycle
(Harper et al., 1993) and as such acts as a potential tumor
suppressor gene. In normal cells, p21 is under p53 control. In
the presence of DNA damage, the axis p53-p21 is activated
and cells are blocked at G1/S to be repaired or addressed
toward cell death. In tumor cells, p53 is often mutated, so that
cells escape the G1 check point and proliferate. Dohh2 lym-
phoma cells have a functional p53 negatively controlled by
BCL6,whichalso inhibits p21 transcription. Thesepositive and
negative feedbacks of p21 expression suggest that a tightly
controlled expression of the tumor suppressor gene p21 is
functional to Dohh2 cell proliferation. Hypothetically, the
upregulation of p21 uncoupled from BCL6 and p53 is ex-
pected to restore the tumor suppressor activity in Dohh2 cells.
Recently, it has been shown that the transfection of a
double-stranded RNA (ds-RNA) of 21 nt specific for the
promoter region of p21 is able to induce the overexpression of
p21 at transcriptional and translational levels in several tumor
cell lines ( Janowski et al., 2006b; Chen et al., 2008; Yang et al.,
2008; Whitson et al., 2009). This process, named RNA acti-
vation (RNAa), acts opposite to RNA interference (RNAi)
(Poliseno et al., 2004) in that the overexpression instead of
underexpression of a given gene is triggered. The existence of
RNA activators derives from several observations. A short
RNA isolated in neuronal staminal cells is able to induce
neural differentiation in adult staminal cells by targeting
NRSE/RE1 (neuronal restrictive elements) (Kuwabara et al.,
2004). A microRNA specific for hepatocytes (miR-122) has
been demonstrated to increase viral replication targeting a
noncoding region at the 50 of viral genome ( Jopling et al.,
2005); moreover, another microRNA (miR-373) was demon-
strated to induce expression of genes with complementary
promoter sequence (Place et al., 2008). Recently, RNAa was
shown to be a mechanism conserved in mammalian cells
(Huang et al., 2010). The main differences between RNA ac-
tivators and RNA inhibitors are the following: first of all, RNA
activator recognizes the promoter of the gene transcription-
ally activated, whereas RNAi recognizes mRNA regions such
as the 30UTR. Second, RNA inhibitors act very rapidly after
transfection, whereas RNA activators act at later times and
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their effect is persistent. Third, RNA activators require the
presence of a 21-nt ds-RNA perfectly complementary at the 50
region (seed region) to DNA target ( Janowski et al., 2006b).
Finally, the proteins necessary for functioning of RNAa and
RNAi are different: AGO1, AGO3, and AGO4 are slightly
involved, whereas AGO2 is fundamental for RNAa ( Janowski
et al., 2006b; Place et al., 2008), even if controversial data on
the role of AGO2 in RNAa also exist ( Janowski et al., 2006a).
In this work, we investigated whether the RNA activator ds-
p21 is able to induce the transcription of p21 in Dohh2 cells and
modify cell proliferation and apoptosis, the 2main responses to
p21 overexpression. We report that the expression of p21 was
transiently enhanced by ds-p21 at themRNAandprotein levels
and that cell proliferation and apoptosis were accordingly but
not significantly modified. In contrast, ds-p21 coupled to flu-
darabine treatment potentiated the death of Dohh2 cells.
Materials and Methods
Double-stranded RNAs
The following ds-RNAs were used: ds-NC (ACUACU
GAGUGACAGUAGA[dT][dT], UCUACUGUCACUCAGU
AGU [dT][dT]) and ds-p21 (CCAACUCAUUCUCCAAGU
A[dT][dT], UACUUGGAGAAUGAGUUG G[dT][dT]) corre-
spond to sequences already used (Li et al., 2006); si-NC
(UUCUCCGAACGUGUCACGUTT, ACGUGACACGUUC
GGAGAATT); si-Bcl6 (GUCGAGACA UCUUGACUGAUU,
UCAGUCAAGAUGUCUCGACUU) corresponds to the se-
FIG. 1. (A) p21 transcription.
Total RNA was extracted and qRT-
PCR was performed at specified
time points after transfection to
quantify p21 transcripts. Each
point represents the expression of
p21 in ds-p21– versus ds-NC–
transfected cells. Data are shown as
SEM from 3 independent experi-
ments (*P< 0.05; **P< 0.01, un-
paired t-test). (B) Expression of p21
protein. ds-NC cells showed a p21
expression similar to that of un-
transfected cells, whereas ds-p21
cells showed an enhanced p21
expression. p21 was detected by
western blot (upper panel)
and quantified by densitometry at
72 hours after double-stranded
RNA (ds-RNA) transfection (lower
panel). Data are shown as SEM
from 3 independent experiments
(*P< 0.05, unpaired t-test). Signals
were normalized to that of b-actin.
(C) Cell proliferation. In compari-
son to untransfected cells, ds-NC–
and ds-p21–transfected cells
showed no significant reduction of
cell proliferation. Data are shown
as SEM from 3 independent ex-
periments. (D) Caspase activity.
Dohh2 transfected cells were dis-
tributed in a 96-well plate and
caspase 3/7 activity was measured
using Caspase-Glo 3/7 Assay.
The luminiscent signal of ds-p21–
transfected cells was no sig-
nificantly higher than that of
ds-NC–transfected cells at 3 days
after transfection. Data are shown
as SEM from 3 independent ex-
periments. (E) Cell cycle analysis.
Bars indicate fold changes (nega-
tive and positive) of cells in G1, S,
and G2 at 3 days after transfection.
Each value was obtained by di-
viding the percentages of ds-p21–transfected cells versus the percentage of ds-NC–transfected cells in each phase. (F) Scat-
tergram of FACS analysis of Dohh2 untransfected (upper panel) and transfected with oligo FITC (lower panel). Transfection
efficiency was *98%.
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quence already used to silence BCL6 (Phan and Dalla-Favera,
2004). All the ds-RNAs were synthesized by GenePharma.
Cell culture
Dohh2 cells and HeLa cells were grown, respectively, in
Roswell Park Memorial Institute 1640 (RPMI 1640) medium
and Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10% fetal calf serum, 2mM l-glutamine, and
penicillin and streptomycin 1% in a humidified atmosphere of
5% CO2 at 378C.
Transfection
Transfection of ds-RNAs was carried out using Amaxa
Nucleofector Device and Nucleofector Solution (Lonza) in
Dohh2 cells. After nucleofection, the cells were distributed in
two 75-cm flasks with 15mL complete medium. HeLa cells
were transfected using Lipofectamine 2000 (Invitrogen).
Cell cycle
At specific times, cells were stained with propidium iodide
and the DNA content profile was determined using FACS-
calibur cytofluorimeter (BD Biosciences).
Caspase activity
Dohh2 cells were distributed in a 96-well plate and caspase
3/7 activity was measured using Caspase-Glo 3/7 Assay
(Promega); the luminiscent signal was read using GloMax-
Multi Detection System (Promega).
RNA extraction
Total RNA was extracted using Trizol Reagent (Invitrogen).
qRT-PCR
Total mRNA was reverse transcribed using QuantiTect
Reverse Trascription Kit (Qiagen). The resulting cDNA sam-
ples were amplified by quantitative Real-Time PCR (qRT-
PCR) using SYBR Green (MesaGreen; Eurogentec) and
LightCycler 480 (Roche). We used specific primers for p21
(forward: TCACTGTCTTGTACCCTTGTGC; reverse: GGCG
TTTGGAGTGGTAGAAA), p53 (forward: AGGCCTTGG
AACTCAAGGAT; reverse: CCCTTTTTGGACTTCAGGTG),
BCL6 (forward: TTCCGCTACAAGGGCAAC; reverse: TGC
AACGATAGGGTTTCTCA), and GAPDH (forward: AGCC
ACATCGCTCAGACA; reverse: GCCCAATACGACCAAA
TCC); amplification of GAPDH served as a loading control.
FIG. 2. (A) Effects of ds-p21
transfection in HeLa cells. Seventy-
two hours posttransfection of either
ds-NC or ds-p21, cells were col-
lected and used to determine the
expression of p21, cell proliferation,
and caspase activity. The fold
changes are calculated by taking as
reference the corresponding values
of ds-NC–transfected cells. Data are
shown as SEM from 3 independent
experiments (**P< 0.01; ***P< 0.001,
unpaired t-test). (B) Expression of
BCL6 protein. Dohh2 cells highly
express the transcriptional repres-
sor BCL6, compared with HeLa
cells. BCL6 was detected by west-
ern blot. (C) Effects of ds-p21 in
BCL6-silenced cells. Dohh2 cells
were prior transfected with an
siRNA against BCL6 and, 48 hours
later, with either ds-NC or ds-p21.
The protein BCL6 was signifi-
cantly reduced in Dohh2 cells
transfected with si-BCL6, whereas
neither ds-NC nor ds-p21 modi-
fied the transcription of p21 in
BCL6-silenced Dohh2 cells (D).
Effects of ds-p21 in HeLa cells.
Dohh2 cells were prior transfected
with either ds-NC or ds-p21 and,
48 hours later, with either si-NC or
ds-p21. In comparison to ds-NCþ
si-NC cells, the expression of p21
was significantly enhanced in ds-
NCþds-p21–, ds-p21þsi-NC–, and ds-p21þds-p21–transfected cells. Data are shown as SEM from 3 independent experi-
ments (*P< 0.05, unpaired t-test). Dashed line shows the reference value (E).
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We performed a relative quantification using fit point
method.
Western blot
Equivalent amounts of protein were resolved on 5%–12%
SDS-PAGE gels and transferred to Hybond-C extra mem-
branes (Amersham Biosciences) by electroblotting. The re-
sulting blots were blocked with 5% BSA solution. We used
anti-ACTB, anti-p21, anti-p53, and BCL6 primary antibodies
(SantaCruz Biotechnologies); immunoblotting secondary an-
tibodies were HRP conjugates (SantaCruz Biotechnologies).
Specific proteins were detected by enhanced chemilumines-
cence (ECL Plus Western Blot Detection Reagent; Amersham
Bioscience).
Results and Discussion
Exponentially growing Dohh2 cells were transfected with
either ds-NC (nick named as ds-NC cells) or ds-p21 specific
for human p21 promoter (nick named as ds-p21 cells). After
transfection, cell suspensions were distributed in a series of
flasks and cultured up to 6 days. After 3 days, cells were
subcultured to restore the optimal cell growth conditions. At
specified time points, cells were collected and used for de-
tection of molecular and cellular endpoints. In comparison to
ds-NC cells, ds-p21 cells showed a significant increase of p21
transcription between 72 and 96 hours after transfection,
which thereafter decreases (Fig. 1A). In accordance with the
enhanced transcription, p21 protein was more expressed in
ds-p21 cells than in ds-NC cells (P< 0.05) (Fig. 1B). At cellular
level, we found that ds-p21 cells proliferate no significantly
less than ds-NC cells (Fig. 1C). In parallel, we measured
apoptotis (Fig. 1D) and analyzed cell cycle (Fig. 1E), which
were both no significantly modified. In this respect, the RNA
activator ds-p21 is biologically irrelevant. There may be many
reasons why the transcription of p21 was not so efficiently
induced by ds-p21 in Dohh2 cells. First of all, we investigated
whether the reduced transcription of p21 was due to a de-
fective transfection. We transfected Dohh2 cells using Amaxa
apparatus and the transfection efficiency was determined
using an oligo FITC. FACS analysis showed that *98% of
cells were FITC positive (Fig. 1F), and therefore, we can rea-
sonably exclude that neither ds-p21 nor ds-NCwas efficiently
transfected. Another possibility is that the ds-p21 used was
not biologically active in Dohh2 cells. To address this point,
either ds-NC or ds-p21 was transfected in HeLa cells. We
found >3-fold increase of the transcription of p21, 2-fold de-
FIG. 3. (A) Dose–response
curve of Dohh2 cells exposed
to increasing concentrations of
fludarabine. After 72 hours of
treatment, cells were counted
and cell proliferation reduction
was calculated. (B) Caspase
activity in fludarabine-treated
cells. The caspase 3/7 activity
of cells exposed to specified
fludarabine concentrationswas
measured using Caspase-Glo
3/7 Assay. (C) Dot plot of cell
proliferation reduction versus
caspase activity. Effects of
0.3mg/mL fludarabine on (D)
Quantification (left panel) of
p53, p21 and BCL6 protein
(right panel); (E) cell prolifera-
tion; and (F) caspase activity.
Data are shown as SEM from 3
independent experiments (*P<
0.05; **P< 0.01, unpaired t-
test).
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crease of cell proliferation, and 3-fold increase of apoptosis in
HeLa cells transfected with ds-p21 in comparison to HeLa
transfected with ds-NC (Fig. 2A). Together these data indicate
that ds-p21 was active in promoting p21 expression at mo-
lecular and cellular levels in HeLa cells and suggest that
Dohh2 cells are refractory to the RNA activator ds-p21. Many
explanations have been so far evoked to explain RNAa.One of
them is that the transcriptional activity is due to chromatin
remodeling. The chromatin associated with genes susceptible
to RNAa has been shown to have demethylated ( Janowski
et al., 2006b) or methylated ( Janowski et al., 2006a) histone H3
lysines. The demethylation of CpG islands seems also to favor
RNAa ( Janowski et al., 2006b). Finally, the position of ds-
RNA is fundamental ( Janowski et al., 2006a): the shift of a
single base of the positioning of the ds-RNA could lead to
activation or inhibition. This indicates that optimal position
sites exist, but whether they are common or not to each gene is
still unknown. As the observed increase of p21 in Dohh2 cells
is much less and less persistent than that found in other tumor
cell lines (Li et al., 2006), it seems plausible that the epigenetic
context of Dohh2 cells is at the basis of the slight RNAa. In
HeLa cells, RNAa has been reported to be methylation de-
pendent (Li et al., 2006). Nevertheless, in HeLa cells and fol-
licular lymphomas, the p21 promoter is not hypermethylated
(Ying et al., 2004). No data are available on the hypermethy-
lation of p21 promoter in Dohh2 cells. However, epigenetic
mechanisms of p21 gene regulation involve also histone
methylation and deacetylation (Duan et al., 2005; Ocker
and Schneider-Stock, 2007; Kim et al., 2009). As histone
deacetylase inhibitors trichostatin A, phenylbutyrate, and
subercylanilide hydroxamic acid can also activate p21 ex-
pression, the possibility of epigenetic repression of this gene
cannot be ruled out (Richon et al., 2000; Sakajiri et al., 2005).
Dohh2 cells express high level of BCL6 (Fig. 2B). BCL6 is a
bifunctional protein consisting of 2 functional domains, a
N-terminal POZ (Poxvirus and zinc finger) domain and
a C-terminal kruppel-type (C2H2) zinc finger domain. The
C-terminal zinc fingers mediate specific DNA recognition and
binding,whereas theN-terminal POZdomain recruits histone
deacetylase repressing transcription (Pasqualucci et al., 2003).
BCL6 is able to repress both p53 (Phan and Dalla-Favera,
2004) and p21 (Phan et al., 2005). To circumvent the epigenetic
control of BCL6, we transfected Dohh2 cells prior with a
siRNA specific for BCL6 to reduce the endogenous BCL6 and
then with either ds-NC or ds-p21 to test whether the tran-
scription of p21 takes advantage from BCL6 reduction. As
expected, we observed a significant reduction of BCL6 in si-
BCL6–transfected cells in comparison to si-NC–transfected
cells (Fig. 2C). Nonetheless, despite this reduction, the ex-
pression of p21 in ds-NC– and ds-p21–transfected cells was
similar (Fig. 2D), suggesting that the residual endogenous
BCL6 is still sufficient to repress the transcription of p21.
However, it cannot be excluded that the lack of ds-p21 effect
in si-BCL6–transfected cells might be due to a reduced
availability of the RNAi apparatus. To address the point, we
transfected HeLa cells, which have a negligible expression of
BCL6 (Fig. 2B), with ds-NC and, 48 hours later, with either si-
NC or ds-p21. Cells were collected at 48 hours after the second
transfection. The expression of p21 was enhanced in ds-
NCþds-p21 cells (column 2) in comparison to ds-NCþsi-NC
cells (column 1), suggesting ds-p21 is not competed by ds-NC.
By transfecting HeLa cells prior with ds-p21 and then with
either si-NC or ds-p21, we found that the expression of p21
was enhanced in both ds-p21þsiNC (column 3) and ds-
p21þds-p21 (column 4), suggesting that ds-p21 is not com-
peted by si-NC. These data suggest that the RNAi apparatus
is not a limiting step in the activation of ds-p21 and so it is
plausible that the poor responsiveness of Dohh2 cells to the
RNA activator ds-p21 is attributable to the epigenetic context
established by the BCL6 overexpression in these cells.
FIG. 4. Dohh2 cells transfected
with either ds-NC or ds-p21 were
exposed or not to 0.3mg/mL flu-
darabine. After 72 hours, the ex-
pression of p53 and p21 proteins
(A), cell proliferation (B), caspase
activity (C), and cell cycle (D) were
measured. The ratio (ds-p21/
ds-NC) of unexposed cells was
used to normalize the ratio (ds-
p21/ds-NC) of exposed cells. Data
are shown as SEM from 3 inde-
pendent experiments (*P< 0.05;
**P< 0.01; ***P< 0.001, unpaired
t-test).
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The finding that the modifications of cell proliferation, cell
cycle, and apoptosis albeit coherent to the enhanced expres-
sion of p21 were not significantly modified (Fig. 1C–E) does
not exclude that the RNA activator ds-p21 could have a bio-
logical role. To give support to this interpretation, we chal-
lenged Dohh2 cells with fludarabine, a drug of prominent
use in hematopoietic malignancies and exhibiting indolent
growth profiles. The choice of this drug was due to the fact
that modulating agents to potentiate fludarabine cytotoxicity
or circumvent fludarabine resistance have been yet consid-
ered (Alas et al., 2000; Anderson and Perry, 2007). To address
whether the RNA activator ds-p21 can act as a modulating
agent of fludarabine cytotoxicity, first of all we determined
the sensitivity of Dohh2 cells to the drug. The dose–response
curve showed that at increasing concentrations of fludar-
abine, cell proliferation decreases (Fig. 3A) and caspase ac-
tivity increases (Fig. 3B). The dot plot of cell proliferation
reduction versus caspase activity showed that the reduction
of cell numbers correlates well with the increase of caspase
activity (r2¼ 0.9736) (Fig. 3C). Then we measured the ex-
pression of p53, p21, and BCL6 in Dohh2 cells at increasing
concentrations of fludarabine and selected 0.3 mg/mL, be-
cause at this concentration p53 was significantly enhanced,
whereas p21 and BCL6 were stably expressed (Fig. 3D). The
cellular outcomes of the exposure to 0.3 mg/mL fludarabine
were a significant reduction of cell proliferation (Fig. 3E) and
an increase of apoptosis (Fig. 3F), suggesting that both the
effects are attributable to the overexpression of p53without an
apparent contribution of p21 because fludarabine per se is not
able to induce p21 expression. Then, we tested whether ds-
p21 can act as a modulating agent of fludarabine cytotoxicity.
For that, Dohh2 cells, transfected with either ds-p21 or ds-NC,
were grown for 3 days in the presence or absence of 0.3 mg/
mL fludarabine. In comparison to ds-NC (þf) cells, ds-p21
(þf) cells showed both p53 and p21 transcriptional increases
(Fig. 4A) and a potentiated reduction of cell proliferation (Fig.
4B) accompanied by a further potentiation of apoptosis (Fig.
4C). Moreover, we observed that ds-p21 (þf) cells more than
ds-NC (þf) cells showed a marked exit from G2 followed by
an accumulation in G1, a state that renders cells particularly
prone to apoptosis (Fig. 4D). The 2-fold reduction of cell
proliferation accompanied by an enhanced caspase activity,
on one hand, highlights a role of the RNA activator p21 as a
modulating agent of fludarabine cytotoxicity and, on the
other hand, indicates that this occurs via the potentiation of
the apoptotic pathways. This means that ds-p21 and fludar-
abine work cooperatively and that ds-p21 is able to enhance
the cytotoxic effect of fludarabine in Dohh2 cells, even if it has
weak effects in these cells when tested alone.
In conclusion, we demonstrated that (1) Dohh2 cells
are poorly responsive to the RNA activator ds-p21, as the
enhanced expression of p21 was unable to affect cell prolif-
eration and apoptosis, the 2 main responses to p21 over-
expression; and (2) the RNA activator ds-p21 potentiates
the responsiveness of Dohh2 cells to fludarabine, suggesting
that ds-p21 molecule could be used as a modulating agent
of fludarabine cytotoxicity.
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